Author Archives: Vijaya Iyer, PhD

Many ANCA-associated Vasculitis Patients Develop Hypersensitivity to Azathioprine, Study Shows

Nearly one in 10 ANCA-associated vasculitis (AAV) patients receiving azathioprine as a maintenance treatment for their condition develop hypersensitivity to the therapy, which manifests as whole body inflammation and skin eruptions, increasing the risk of relapse. Researchers should be aware of this complication, which is more common than previously thought, to…

Minimal Glucocorticoid Regimen Shows Similar Efficacy, Fewer Adverse Events than Standard Treatments, Study Reports

Patients with ANCA-associated vasculitis (AAV) who receive a minimal glucocorticoid treatment along with Rituxan (rituximab) and cyclophosphamide show similar improvement as those given standard glucocorticoid regimens, but have lower glucocorticoid-associated adverse events, a study shows. The study, “A novel glucocorticoid-free maintenance regimen for anti-neutrophil cytoplasm antibody–associated vasculitis,” was published…

Biopsy Combined with Other Tests Can Better Predict Kidney Survival, Study Finds

Patients with ANCA-associated vasculitis (AAV) who have renal symptoms might benefit from a kidney biopsy along with measurements of ANCA antibodies and kidney function to predict their renal outcomes, a Chinese study reported. The study, “An evaluation of the 2010 histopathological classification of anti-neutrophil cytoplasmic antibody (ANCA)-associated glomerulonephritis: a…